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Abstract— The aim of the study is to formulate and 
evaluate enteric coated tablets using Isoxsuprine 
Hydrochloride as a model drug. Different core tablets and 
enteric coated tablets were prepared and drug release was 
studied. Isoxsuprine Hydrochloride core tablets were 
prepared by wet granulation method, using polymers, by 
changing drug ratios. The granules are evaluated for 
physical properties and the in-vitro drug release studies. 
Enteric coating was carried out using different sub coating 
materials. Enteric coating was performed in a mini coating 
pan at 107 rpm using low-pressure air atomized liquid 
spray technique. By changing the coating material, were 
done single coated, Double coated tablets are evaluated for 
uniformity hardness, friability, invitro disintegration and 
dissolution studies. The in-vitro drug release data was fitted 
into various kinetic models. All the formulations showed the 
values within the prescribed limit. It was observed that the 
higher rate and drug release was observed for the double 
coated tablets, this is because second layer having high 
viscosity.  
Keyword— Double coated tablets, disintegration and 
dissolution studies, Enteric coated tablets, formulations, 
Isoxsuprine   Hydrochloride. 
 
I. INTRODUCTION 
Oral route of administration has been received more 
attention in the pharmaceutical field because of the more 
flexibility in the designing of dosage form than drug 
delivery design for other routes. Most of the oral controlled 
drug delivery systems rely on diffusion, dissolution or 
combination of both mechanisms, to release the drug in a 
controlled manner to the Gastrointestinal Tract (GIT) and 
the drug profile data, such as dose, absorption properties 
and the quantity of drug needed, one can determine the 
desired release rate of the drug from1 controlled release 
dosage form. Drugs that are easily absorbed from the G.I.T 
and having a short half-life are eliminated quickly from the 
blood circulation. To avoid this problem the oral controlled 
release formulations have been developed, as these will 
release the drug slowly into the GIT and maintain a constant 
drug concentration in the serum for a longer period of 
time.Isoxsuprine, or Isoxsuprine hydrochloride, is a drug 
used as a vasodilator in humans and equines.  Isoxsuprine is 
most commonly used to treat hoof-related problems in the 
horse. 
Most commonly for laminitis and nonvascular disease, as 
its effects as a vasodilator are thought to increase 
circulation within the hoof to help counteract the problems 
associated with these conditions. Enteric coatings are those, 
which remain intact in the stomach, but they dissolve and 
release the contents once it reaches small intestine.  Their 
prime intension is to delay the release of drugs, drugs 
sensitive to the stomach contents or may cause nausea or 
bleeding by irritation of gastric mucosa. There are three 
reasons for putting such a coating on a tablet or capsule 
Ingredient to protect the stomach, to protect the drug from 
the stomach To release the drug after the stomach e.g. in the 
intestines. The drugs which most commonly cause stomach 
ulcers like aspirin, diclofenac and naproxen are frequently 
available with enteric coatings. Omeprazole, which is a 
drug which stops the stomach from producing acid, is itself 
broken down in acid and therefore the drug generally has an 
enteric coating around it either as a granule in the capsules 
or as a granule in the dispersible form. Sulfasalazine is used 
either for the treatment of arthritis or for the treatment of 
Corn’s disease which is inflammation of the intestines. 
When used for arthritis it is very often given without an 
enteric coating so that it can be absorbed more quickly, 
whereas for Crowns’ where it is needed in the intestines to 
work it is given with an enteric coating. It can be seen that 
an enteric coating is therefore there usually for a good 
reason and therefore such tablets or the contents of enteric 
coated capsules should never be crushed before being taken. 
To formulate and evaluate the Enteric coated tablets using 
Isoxsuprine Hydrochloride as a model drug by using 
different  polymers, to evaluate the granules prepared from 
isoxsuprine Hcl  for: Bulk density, Tapped density. 
Hausners ratio and cars index, to evaluate the  prepared  
enteric coated  tablets for: physical properties,Invitro  drug 
release studies, Drug release mechanism2.3. 
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II. MATERIALS AND METHODS 
Table.1: Selected excipients for formulations 
S.no Name  of   the  Ingredients Category 
1 Crosspovidone Disintegrating agent 
2 Crasscarmellos Sodium Disintegrating agent 
3 HPMC E15 Disintegrating  agent 
4 Carbapol Disintegrating  agent 
5 PVPK30 Binder 
6 Sodium 
carbonate Alkalizing   agent 
7 Mannitol Diluent 
8 Magnesium  Stearate Lubricant 
9 Talc Glidant 
10 Isopropyl alcohol Solvent 
 
Preparation of core tablets 4,5: 
The core tablets were prepared by wet granulation method. 
All the ingredients (show in Table 1), were mixed and 
passed through sieve no. 40 to get uniformally distributed 
and uniform sized particles. These granules are compressed 
on a single punching tablet machine. One batch of 20 
tablets were  prepared. 
Preparation of enteric coated tablets: 
The prepared core tablets were taken, for a single 2coating 
process. It has two coatings, coated with cellulose acetate 
phthalate and HPMC .Required quantity of coating 
materials were added slowly to the vortex zone and the 
suspensions was mixed for 1hr.45 min.for single coated 
tablets and for double coated tablets was maintained 
without air bubbles then use the solution was used for 
coating4. The tablets were placed in a coating pan till the 
average weight as per the specifications (given in table 3). 
Table.2: Selected Enteric Coated Materials 
S.no Name  of  ingredients Category 
 Sub coating  
1 HPMC 
Sub 
coating  
materials 
2 Cellulose  acetate phthalate 
Sub 
coating  
materials 
3 Isopropyl alcohol Solvent 
 Enteric  coating 
4 Meth acrylic acid 
Enteric  
coating 
material 
5 Titanium di oxide Coloring  
agent 
 
Table.3: Specifications of Sub coating 
Inlet temp(oc) 60-65 
Out let temp(oc) 40-45 
Spray gun rpm 2-3 
Air pressure(kg/cm2) 4-5 
 
Analytical method /Standard calibration of curve of 
Isoxsuprine 
 Hcl (pure drug) in suitable solvent 
 
Fig.1: UV scanning image of pure Isoxsuprine hcl drug in 
solvent chloroform 
Calibration curve for Isoxsuprine Hcl drug:                            
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Cumulative analysis of Granules: 
Table.4: Particle size of Granules 
Granulates 
(wt%) 
Mean  
thickness(µm) 
Diameter of  
granules(µm) 
Particle  
Size(µm) 
3.0 52 30 0.0128 
6.0 61 30 0.0226 
9.0 75 30 0.0351 
12.o 102 40 0.0425 
15.o 110 40 0.0565 
18.0 123 40 0.0638 
Total 
weight=21.0 123 30 0.0772 
 
Table.5: Pre compression   properties of uncoated   tablets 
S.n
o 
Formulati
on code 
Bulk  
density 
Tapped  
density 
Carr’s 
index (%) 
Hauser
’s ratio 
(%) 
1 F1 0.472 0.509 7.27 1.079 
2 F2 0.374 0.398 6.03 1.064 
3 F3 0.398 0.425 6.26 1.066 
4 F4 0.404 0.432 6.48 1.069 
5 F5 0.472 0.509 7.27 1.079 
6 F6 0.447 0.481 7.07 1.075 
 
Table. 6: Post compression properties of Isoxsuprine Hcl 
uncoated tablets: 
S.n
o 
Formul
ation 
code 
Thick
ness 
(mm) 
Diamet
er 
(mm) 
Hardn
ess(k
g/cm2
) 
Friabi
lity 
(%) 
Weig
ht 
variat
ion 
(mg) 
1 F1 
4.0±0.
03 9.0 4.4 0.623 
393±
0.25 
2 F2 
3.9±0.
04 9.0 4.1 0.716 
398±
0.30 
3 F3 
3.9±0.
05 9.0 4.6 0.657 
397±
0.28 
4 F4 
4.0±0.
04 9.0 4.4 0.701 
398±
0.04 
5 F5 
3.8±0.
06 9.0 4.3 0.664 
396±
0.32 
6 F6 
3.8±0.
07 9.0 4.2 0.622 
401±
0.16 
 
 
Table.7: Post compression properties of Isoxsuprine Hcl 
single coated tablets: 
S.n
o 
Formu
lation 
code 
Thickness 
(mm) 
Diameter 
(mm) 
Hardness 
(Kg/cm2) 
Friability 
test 
1 Fs 4.8±0.03 9.5 4.9 0.697 
2 Fs 5.0±0.04 9.5 4.8 0.724 
3 Fs 4.9±0.05 9.5 5.1 0.65 
4 Fs 5.0±0.04 9.5 4.9 0.73 
5 Fs 4.8±0.06 9.5 5.2 0.85 
6 Fs 5.0±0.07 9.5 4.8 0.80 
7 Fs 4.9±0.02 9.5 4.9 0.83 
8 Fs 5.0±0.03 9.5 5.0 0.82 
 
Table.8: Post compression properties of Isoxsuprine Hcl 
double coated tablets: 
S.no 
Formul
ation 
code 
Thickness 
(mm) 
Diameter 
(mm) 
Hardness 
(Kg/cm2) 
Friability 
test 
1 Fd 5±0.03 10.0 5.2 0.85 
2 Fd 5.5±0.05 10.0 5.4 0.76 
3 Fd 5.4±0.05 10.0 5.2 0.89 
4 Fd 5.5±0.06 10.0 5.2 0.91 
5 Fd 5.3±0.03 10.0 5.5 0.88 
6 Fd 5.3±0.04 10.0 5.4 0.86 
7 Fd 5.5±0.04 10.0 5.3 0.88 
8 Fd 5.4±0.03 10.0 5.4 0.92 
  
Table.9: In vitro studies of Isoxsuprine Hcl uncoated tablets 
Ti
me 
Cumulati
ve drug 
release 
(%)F1 
Cumula
tive 
drug 
release 
(%) F2 
Cumu
ltive  
drug  
releas
e(%)
F3 
Cumu
ltive  
drug 
releas
e(%)F
4 
Cumul
tive  
drug  
releas
e(%)F
5 
Cumu
ltive  
drug  
releas
e(%)F
6 
0 0 0 0 0 0 0 
30 9.9 7.1 8.1 10.25 7.65 8.21 
60 12.5 11.6 14.0 16.6 15.3 16.25 
90 15.8 16.5 19.5 23.8 33.3 20.25 
120 18.4 19.8 25.3 31.9 42.3 27.9 
150 22.8 25.3 29.7 47.05 39.06 38.3 
180 27.1 32.5 36.04 49.6 42.7 43.8 
210 35.4 38.2 39.6 54.8 50.85 49.4 
240 47.89 47.1 45.0 59.03 54.8 56.92 
270 58.99 57.5 58.2 61.8 59.6 58.2 
300 62.8 65.3 64.05 68.04 61.5 63.7 
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330 69.3 69.6 66.3 70.25 65.9 63.7 
360 72.57 76.5 76.7 75.6 71.3 69.9 
390 78.4 79.01 79.0 79.21 75.8 73.1 
420 85.2 85 83.5 81.3 77.2 75.9 
450 89.6 89.9 85.2 84.5 79.6 79.8 
480 94.5 93.4 88.9 85.3 80.6 81.5 
In vivo drug release for all formulations: 
 
 
Drug release of enteric coated tablets: 
Table.10: Invitro drug release of single coated tablets 
Time   
( min) 
Cumulative 
drug 
release 
(%)Fs 
Cumulative 
drug release 
(%)Fs 
Cumulative 
drug release 
(%)Fs 
Cumul
ative 
drug 
release 
(%)Fs 
0 0 0 0 0 
30 15.7 14.8 15.8 18.6 
60 29.8 30.6 25.9 29.3 
90 35.6 34.8 38.2 39.5 
120 48.2 49.6 47.8 49.6 
150 55.6 55.7 59.5 55.7 
180 79.6 69.8 66.6 68.2 
210 75.2 79.8 73.2 77.8 
240 81.2 84.3 78.4 79.1 
270 85.4 88.6 81.4 84.5 
300 89.2 89.2 83.2 91.1 
330 94.5 92.4 93.5 92.3 
 
 
 
Table.11: Double   coated   tablets 
Time(mi
n) 
Cumulati
ve drug 
release Fd 
Cumulati
ve drug 
release Fd 
Cumulati
ve drug 
releaseFd 
Cumulati
ve drug 
releaseFd 
0 0 0 0 0 
30 28.6 29.8 34.8 36.9 
60 41.5 45.9 45.9 48.4 
90 58.4 57.3 51.6 53.4 
120 63.5 67.8 59.4 58.9 
150 83.4 71.3 69.7 59.8 
180 88.9 79.3 78.7 63.8 
210 92 81.3 79 63.8 
240 93.2 86.8 80.6 79 
270 94.8 89.8 82.4 82.1 
300 94.8 92.6 85.3 90.5 
330 95.8 94.5 86.9 92.3 
  
 
Table.12:The invitro disintegration studies for coated 
tablets 
S.no Single coated  
tablets  
Disintegrating time 
1 FS11 3hrs 
2 FS12 2hr.30min 
3 FS21 2hrs 
4 FS22 2hr.30min 
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Table.13: Double coated tablets 
S.no Double  coated 
tablets  
Disintegrating time 
1 Fd11 2hrs 
2 Fd12 1.30min 
3 Fd21 2hrs 
4 Fd22 2hrs 
 
III. CONCLUSIONS 
From the present  study  we  conclude  that, amongst the all  
polymers  studied,HPMC has  shown  has shown  best drug 
release. Of the two coatings i.e. single coated, double 
coated tablets as shown best drug release. From the 
Disintegration and dissolution  studies, it  is  observed  that, 
in double coated  tablets, drug will  release faster than  other  
coatings  because  the  second layer  is  made  up  of  high 
viscosity  material.(because  of coat thickness 5.5±0.05 and 
viscosity 4000cps).All  the formulations are satisfactory 
with a proper  disintegration time. In the case  of uncoated 
tablets  drug release is slower, where  as  in  coated  tablets 
drug release is  observed  to  be faster. Enteric coated tablets  
are  easily  dissolved  in the dissolution  apparatus(it is at 
pH 6.8),hence  will  dissolve  in Gastro  intestinal tract 
which  is also  at  pH 6.8.For Isoxsuprine hydrochloride  
coating  is necessary, as  it  makes  the unpleasant taste and  
gives a smooth finish.  
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